Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .
Effects of erythropoietin on emotional processing biases in patients with major depression: an exploratory fMRI study
Introduction Erythropoietin ( Epo ) has neurotrophic effects and may be a novel therapeutic agent in the treatment of depression . We have found antidepressant-like effects of Epo on emotional processing and mood in healthy volunteers . Objective The current study aim ed to explore the effects of Epo on the neural processing of emotional information in depressed patients . Material s and methods Seventeen patients with acute major depressive disorder were r and omised to receive Epo ( 40,000 IU ) or saline iv in a double-blind , parallel-group design . On day 3 , we assessed neural responses to positive , negative and neutral pictures during fMRI followed by picture recall after the scan . Mood and blood parameters were assessed at baseline and on day 3 . Results Epo reduced neural response to negative vs. positive pictures 3 days post-administration in a network of areas including the hippocampus , ventromedial prefrontal and parietal cortex . After the scan , Epo-treated patients showed improved memory compared with those that were given placebo . The effects occurred in the absence of changes in mood or haematological parameters , suggesting that they originated from direct neurobiological actions of Epo . Conclusions These findings are similar to the effects of conventional antidepressants and opposite to the negative biases in depression . The central effects of Epo therefore deserve further investigation as a potential antidepressant mechanism
Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy , tolerability and acceptability .
Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics , reboxetine and venlafaxine , however , it seemed to be less efficacious than escitalopram .
BACKGROUND Recent US and UK clinical practice guidelines recommend that second-generation antidepressants should be considered amongst the best first-line options when drug therapy is indicated for a depressive episode .
Systematic review s have already highlighted some differences in efficacy between second-generation antidepressants .
Citalopram , one of the first selective serotonin reuptake inhibitors ( SSRI ) introduced in the market , is one of these antidepressant drugs that clinicians use for routine depression care .
OBJECTIVES To assess the evidence for the efficacy , acceptability and tolerability of citalopram in comparison with tricyclics , heterocyclics , other SSRIs and other conventional and non-conventional antidepressants in the acute-phase treatment of major depression .